Posted by Michael Wonder on 28 Sep 2016
Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS
28 September 2016 - Bayer is pleased to announce that NICE has made the final recommendation for aflibercept for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion.
NICE concluded within the final guidance that aflibercept is more cost effective than laser photocoagulation (existing first-line treatment) for untreated visual impairment caused by macular oedema secondary to branch retinal vein occlusion.
NICE also concluded that aflibercept is more clinically effective when given before, rather than after, laser photocoagulation.
Following full guidance, the NHS in England and Wales now has 90 days to implement the guidance to ensure that all eligible patients have access to aflibercept as soon as possible.
